# Perrigo Company plc (PRGO) Stock Analysis: Evaluating a Potential 74.90% Upside in the Healthcare Sector

- Link: https://www.directorstalkinterviews.com/perrigo-company-plc-prgo-stock-analysis-evaluating-a-potential-74-90-upside-in-the-healthcare-sector/4121247305
- Published: 2026-03-31T10:10:19+01:00
- Author: Madison Wilson

Perrigo Company plc (NYSE: PRGO), a key player in the drug manufacturing industry,
offers a compelling opportunity for investors seeking exposure in the healthcare
sector. With its headquarters in Dublin, Ireland, Perrigo operates through two primary
segments—Consumer Self-Care Americas and Consumer Self-Care International—providing
a range of over-the-counter health and wellness products across the globe.

At a current price of $9.72, Perrigo’s stock has experienced significant volatility,
trading within a 52-week range of $9.25 to $28.43. Despite recent challenges, including
a -2.50% revenue growth and a troubling EPS of -10.12, the company is garnering 
investor interest due to its robust dividend yield of 11.93% and a potential upside
of 74.90% as reflected in analyst target prices.

The company’s valuation metrics reveal a forward P/E ratio of 4.06, suggesting that
the stock may be undervalued relative to its earnings potential. However, the absence
of a trailing P/E ratio and other valuation metrics like PEG Ratio, Price/Book, 
and Price/Sales indicates some underlying challenges in the company’s financial 
structure. The market cap stands at $1.34 billion, reflecting its position as a 
significant entity within the specialty and generic drug manufacturing industry.

Performance-wise, Perrigo is facing hurdles, with a return on equity of -38.66%.
Despite this, the company has maintained positive free cash flow of approximately
$28.3 million, which could be a beacon of hope for long-term investors. The dividend
payout ratio of 10,950.00% raises questions about [sustainability](https://www.directorstalkinterviews.com/sustainability-green-stocks-news),
yet it also highlights the company’s commitment to returning value to shareholders.

Analyst ratings provide a mixed but optimistic outlook. With two buy ratings and
three hold ratings, there are no sell recommendations, indicating cautious optimism.
The average target price of $17.00 signifies a substantial potential upside from
the current levels, with target prices ranging between $15.00 and $20.00.

From a technical perspective, the stock has a relative strength index (RSI) of 28.75,
which may indicate that it is currently oversold, presenting a potential buying 
opportunity for contrarian investors. The moving averages—50-day at $12.64 and 200-
day at $18.65—further suggest a bearish trend, yet the MACD and signal line figures,
standing at -0.93 and -1.05 respectively, hint at a possible reversal.

Perrigo continues to leverage its strong brand portfolio, including well-known names
like Compeed, Dr. Fresh, and Nasonex. The company’s broad product lineup spans various
health categories, from upper respiratory to women’s health products, and is widely
distributed through retail drug, supermarket, and e-commerce channels.

Founded in 1887, Perrigo has a long-standing history in the healthcare industry.
The company’s strategic focus on consumer self-care solutions aligns with growing
global consumer trends towards health and wellness, positioning it well for future
growth despite current financial challenges.

For investors looking to diversify their healthcare portfolio, Perrigo Company plc
presents a unique opportunity with significant upside potential. However, it is 
crucial to weigh the risks associated with its current financial performance and
market volatility. As always, conducting thorough due diligence and aligning investment
decisions with personal financial goals and risk tolerance is advisable.

Share on: